Drug InformationPharmacy FAQWhat is online pharmacy?Since about the year 2000, hundreds of pharmacies have begun operating over the internet. What does the term "generic" mean? Do generic medications produce the same effect as the brand name medicines do?The difference between a brand name medicine and a generic one is in the name, shape and in the price. A generic drug is usually called by the name of the active ingredient while a manufacturer uses a brand name... more >> Why are generic medicines so cheap?Generics are much cheaper than brand-name drugs because generic companies do not have overhead cost such as research and marketing. Most generic drugs are manufactured off-shore and sold online. Since manufacturers do not spend on advertising, research, and creating a physical store, the ... more >> Are generic drugs as reliable as brand name pills?Generic drugs are tested under the same standards as brand-name drugs. Each generic drug is laboratory tested so that the same amount is absorbed into the body as with brand-name drugs. Generic pills do not look like the brand name medication. The pills have a different name printed on them. Why?As we have already mentioned that no manufacturer can take out a patent for a chemical agent. Thus generics can have the exactly same active ingredients as the brand pills. However, names and appearance (shape an... more >> Are generic drugs patented?No, but having a patent does not make it any more reliable. ... more >> |
special offers
Mebendazole (Systemic)VA CLASSIFICATION Primary: AP200 Commonly used brand name(s): Vermox. Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s). Category: Anthelmintic (systemic)— Indications Note: Bracketed information in the Indications section refers to uses that are not included in U.S. product labeling. Accepted Ascariasis (treatment)—Mebendazole is indicated as a primary agent for ascariasis caused by Ascaris lumbricoides (common roundworm). Enterobiasis (treatment)—Mebendazole is indicated as a primary agent for enterobiasis caused by Enterobius vermicularis (pinworm). Hookworm infection (treatment)—Mebendazole is indicated as a primary agent for hookworm disease caused by Ancylostoma duodenale (common hookworm; Old World hookworm) and Necator americanus (American hookworm; New World hookworm). Intestinal roundworm, multiple (treatment)—Mebendazole is indicated in the treatment of multiple intestinal roundworm infections. Trichuriasis (treatment)—Mebendazole is indicated as a primary agent for trichuriasis caused by Trichuris trichiura (whipworm). [Capillariasis (treatment)]—Mebendazole is used in the treatment of capillariasis caused by Capillaria philippinensis . [Gnathostomiasis (treatment)]—Mebendazole is used in the treatment of gnathostomiasis caused by Gnathostoma spinigerum . [Hydatid disease, alveolar (treatment) ]—Mebendazole is used in the treatment of alveolar hydatid disease caused by Echinococcus multilocularis (E. alveolaris) . [Hydatid disease, unilocular (treatment) ]—Mebendazole is used in the treatment of unilocular hydatid disease caused by E. granulosus . Mebendazole is used as a secondary agent in patients in whom surgery is contraindicated or has failed, in after-spill during surgery, or in recurrences. Very high doses may be effective. [Trichinosis (treatment)]—Mebendazole is used as a secondary agent in the treatment of trichinosis (trichinellosis) caused by Trichinella spiralis (pork worm). Systemic corticosteroids are used concurrently, especially in patients with severe symptoms, to minimize inflammatory reactions to Trichinella larvae. —Not all species or strains of a particular helminth may be susceptible to mebendazole. In addition, efficacy varies with respect to pre-existing diarrhea, gastrointestinal transit time, and degree of infection. 1 Not included in Canadian product labeling. Pharmacology/Pharmacokinetics Physicochemical characteristics: Molecular weight— 295.30 Mechanism of action/Effect: Vermicidal; may also be ovicidal for ova of most helminths; mebendazole causes degeneration of parasite's cytoplasmic microtubules and thereby selectively and irreversibly blocks glucose uptake in susceptible adult intestine-dwelling helminths and their tissue-dwelling larvae; inhibition of glucose uptake apparently results in depletion of the parasite's glycogen stores; this, in turn, results in reduced formation of adenosine triphosphate (ATP) required for survival and reproduction of the helminth; corresponding energy levels are gradually reduced until death of the parasite ensues; mebendazole does not appear to affect serum glucose concentrations in humans, however. Absorption: Poorly absorbed (approximately 5 to 10%) from gastrointestinal tract ; absorption may be increased when taken with food, especially fatty food. Distribution: Distributed to serum, cyst fluid, liver, omental fat, and pelvic, pulmonary, and hepatic cysts; highest concentrations found in liver; relatively high concentrations also found in muscle-encysted Trichinella spiralis larvae; also crosses the placenta. Protein binding: High to very high (90–95%). Biotransformation: Primarily hepatic; metabolized to inactive amino, hydroxy, and hydroxyamino metabolites; primary metabolite is 2-amino-5-benzoylbenzimidazole. Half-life: Normal hepatic function—2.5 to 5.5 hours (range: 2.5 to 9 hours). Impaired hepatic function (cholestasis)—Approximately 35 hours. Time to peak serum concentration 2 to 5 hours (range—0.5 to 7 hours). Peak serum concentration Following a dose of 100 mg twice a day for 3 days: Mebendazole: Not more than 0.03 mcg per mL. 2-Amino metabolite: Not more than 0.09 mcg per mL. Serum concentrations up to 0.5 mcg per mL have been reported in chronic, high-dose therapy. Elimination: Fecal—Approximately 95% excreted unchanged or as the primary metabolite (2-amino derivative) in feces. Renal—Approximately 2 to 5% excreted unchanged or as the primary metabolite in urine. Precautions to Consider Carcinogenicity Carcinogenicity studies in mice and rats given doses as high as 40 mg per kg of body weight (mg/kg) daily for over two years have not shown mebendazole to be carcinogenic. Mutagenicity Dominant lethal mutation studies in mice given single doses as high as 640 mg/kg have not shown that mebendazole is mutagenic. The spermatocyte test, the F 1 translocation test, and the Ames test produced negative results. Pregnancy/Reproduction Fertility— Studies in mice given doses of up to 40 mg/kg for 60 days prior to gestation in males and 14 days in females have not shown that mebendazole causes adverse effects on the fetus or offspring. However, mebendazole has been shown to cause slight maternal toxicity at this dose. Pregnancy— Mebendazole crosses the placenta. A post-marketing survey in pregnant women who inadvertently took mebendazole during the first trimester has not shown an incidence of spontaneous abortion or malformation greater than that of the general population. In a total of 170 deliveries at term, mebendazole has not been shown to be teratogenic in humans. Studies in rats given single oral doses as low as 10 mg/kg have shown that mebendazole is teratogenic and embryotoxic. FDA Pregnancy Category C. Breast-feeding It is not known whether mebendazole is distributed into breast milk. However, problems in humans have not been documented. Pediatrics Appropriate studies on the relationship of age to the effects of mebendazole have not been performed in children up to 2 years of age. However, no pediatrics-specific problems have been documented to date in children over the age of 2. Geriatrics No information is available on the relationship of age to the effects of mebendazole in geriatric patients. Drug interactions and/or related problems The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate)—not necessarily inclusive (» = major clinical significance): Note: Combinations containing any of the following medications, depending on the amount present, may also interact with this medication. Carbamazepine (in patients receiving high doses of mebendazole for treatment of tissue-dwelling organisms such as Echinococcus multilocularis or E. granulosus [hydatid disease], carbamazepine has been shown to lower mebendazole plasma concentrations by induction of hepatic microsomal enzymes and to impair the therapeutic response; if carbamazepine is being used for seizures, replacement with valproic acid is recommended; treatment of intestinal helminths such as whipworms or hookworms does not appear to be affected by the rate of hepatic metabolism of mebendazole) Laboratory value alterations The following have been selected on the basis of their potential clinical significance (possible effect in parentheses where appropriate)—not necessarily inclusive (» = major clinical significance): With physiology/laboratory test values » Alanine aminotransferase (ALT [SGPT]), serum, and » Alkaline phosphatase, serum, and » Aspartate aminotransferase (AST [SGOT]), serum, and Blood urea nitrogen (BUN) (values may be transiently increased ) Hemoglobin, serum (concentration may be decreased ) Medical considerations/Contraindications The medical considerations/contraindications included have been selected on the basis of their potential clinical significance (reasons given in parentheses where appropriate)— not necessarily inclusive (» = major clinical significance). Risk-benefit should be considered when the following medical problems exist Crohn's ileitis or Ulcerative colitis (may increase absorption and toxicity of mebendazole, especially in high-dose therapy) » Hepatic function impairment (mebendazole is metabolized primarily in liver; prolonged half-life and drug accumulation may occur, with an increased incidence of side effects; dosage may need to be decreased ) Hypersensitivity to mebendazole Patient monitoring The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition; » = major clinical significance): For pinworms » Perianal examinations (cellophane tape swabs of the perianal area to detect the presence of eggs may be required prior to and starting 1 week following treatment with mebendazole, especially in patients with persisting symptoms; swabs should be taken every morning prior to defecation and bathing for at least 3 days to determine efficacy or proof of cure; perianal examinations may also be required to detect the presence of adult worms in the perianal area; no patient should be considered cured unless perianal swabs have been negative for 7 consecutive days) For roundworms, whipworms, and capillariasis » Stool examinations (may be required prior to and approximately 1 to 3 weeks following treatment with mebendazole to determine efficacy or proof of cure; because of colonic mixing, eggs may persist in the stool for up to 1 week following cure) For patients on high-dose therapy » Complete blood counts (CBCs) (may be required prior to and periodically during the first month of treatment with mebendazole since high-dose mebendazole may cause granulocytopenia, neutropenia, and/or leukopenia; CBC's performed two or three times a week from day 10 through day 25, and weekly thereafter, are recommended) Side/Adverse Effects The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate)—not necessarily inclusive: Those indicating need for medical attention Incidence rare Hypersensitivity (fever; skin rash or itching) neutropenia (sore throat and fever; unusual tiredness and weakness)—with high doses, reversible Those indicating need for medical attention only if they continue or are bothersome Incidence less frequent Gastrointestinal disturbances (abdominal pain or upset; diarrhea; nausea or vomiting) Incidence rare Alopecia (hair loss)—with high doses dizziness headache Overdose For more information on the management of overdose or unintentional ingestion, contact a Poison Control Center (see ). In accidental overdose, gastrointestinal symptoms may occur and may last up to a few hours. Treatment of overdose Supportive care: Supportive therapy necessary to maintain the vital functions of the patient may be administered. Patient Consultation As an aid to patient consultation, refer to Advice for the Patient, Mebendazole (Systemic). In providing consultation, consider emphasizing the following selected information (» = major clinical significance): Before using this medication » Conditions affecting use, especially: Hypersensitivity to mebendazole Pregnancy—Mebendazole crosses the placenta Other medical problems, especially hepatic function impairment Proper use of this medication Reading patient instructions before taking medication No special preparations or other measures (e.g., dietary restrictions or fasting, concurrent medications, purging, or cleansing enemas) required before, during, or immediately after therapy Chewing tablets, swallowing whole, or crushing tablets and mixing with food » Compliance with full course of therapy; second course may be required in some infections » Proper dosing Missed dose: Taking as soon as possible; not taking if almost time for next dose; not doubling doses » Proper storage For pinworms Treating all household members concurrently; treating again in 2 to 3 weeks For patients on high-dose therapy » Taking with meals, especially fatty ones, to increase absorption; checking with physician if on low-fat diet Precautions while using this medication Regular visits to physician to check progress, especially in high-dose therapy Checking with physician if no improvement within a few days For hookworms or whipworms Importance of taking iron supplements daily during treatment and for up to 6 months following treatment if patient is anemic at the time of therapy For pinworms Washing (not shaking) all bedding and nightclothes after treatment to prevent reinfection Other measures may be recommended by some physicians Side/adverse effects Signs of potential side effects, especially hypersensitivity and neutropenia General Dosing Information No special preparations (e.g., dietary restrictions or fasting, concurrent medications, purging, or cleansing enemas) are required before, during, or immediately after treatment with mebendazole. Mebendazole tablets may be chewed, swallowed whole, or crushed and mixed with food. Patients who are heavily infected with helminths may require more prolonged treatment. For high-dose therapy In the treatment of tissue-dwelling helminth infections, the administration of much higher doses of mebendazole may be necessary because of poor absorption. Mebendazole should preferably be taken with meals, especially fatty ones. This increases the bioavailability, absorption, and serum concentrations of mebendazole. For hookworms and whipworms In the treatment of hookworms and whipworms, especially in patients who are heavily infected or who have inadequate dietary intake of iron, concurrent iron therapy may be required if anemia is present. Iron therapy may need to be continued for up to 6 months to replenish iron stores. For pinworms Because of the high probability of transfer of pinworms, it is usually recommended that all members of the household be treated concurrently. Retreatment is recommended 2 to 3 weeks following initial treatment. Oral Dosage Forms Note: Bracketed uses in the Dosage Forms section refer to categories of use and/or indications that are not included in U.S. product labeling. MEBENDAZOLE TABLETS (CHEWABLE) USP Usual adult and adolescent dose Ascariasis; or Trichuriasis; or Hookworm Oral, 100 mg two times a day, morning and evening, for three days. May be repeated in two to three weeks if required. Enterobiasis Oral, 100 mg as a single dose. Repeat in two to three weeks. Intestinal roundworm, multiple Oral, 100 mg two times a day, morning and evening, for three days. [Capillariasis] Oral, 200 mg two times a day for twenty days. [Gnathostomiasis] Oral, 200 mg every three hours for six days. [Hydatid disease] Oral, 13.3 to 16.7 mg per kg of body weight three times a day for up to three to six months. [Trichinosis] Oral, 200 to 400 mg three times a day for three days, then 400 to 500 mg three times a day for ten days. Usual adult prescribing limits [Hydatid disease]—Doses up to 200 mg per kg of body weight daily have been used. Usual pediatric dose Children up to 2 years of age—Dosage has not been established. Children 2 years of age and over—Ascariasis, [capillariasis] , enterobiasis, intestinal roundworm infections, trichuriasis, and uncinariasis: See Note: In the treatment of infections caused by tissue-dwelling organisms in which high doses are required, dosage should be based on the patient's body weight. Strength(s) usually available U.S.— 100 mg (Rx) [Vermox][Generic] Canada— 100 mg (Rx) [Vermox (scored)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Auxiliary labeling: • May be chewed, crushed, or swallowed whole. • Take with meals (high-dose therapy). • Continue medication for full time of treatment. Professional Information |
Online PharmacyOnline Pharmacy (US)Trusted Pharmacy (World)Online Pharmacy (ED)AggregationMeds NewsU.S. medical programs missing millions of kids: reportReuters - An estimated five million uninsured children in the United States were eligible for Medicaid or the Childrens Health Insurance Program (CHIP) but were not enrolled in either plan, according to a new report... more >>Fri, 03 Sep 2010 Prescription Drug Use Rising in U.S., CDC ReportsHD - Over the last 10 years, the percentage of Americans who took at least one prescription drug in the past month increased from 44 percent to 48 percent, says a federal government study released Thursday... more >>Fri, 03 Sep 2010 Some donated malaria drugs being stolen in AfricaAP - Millions of free malaria drugs are sent to Africa every year by international donors. New research is now providing evidence for what health workers have long suspected: some of the donated medication is being stolen and resold on commercial markets... more >>Wed, 01 Sep 2010 Child health at risk from non-prescription drugs: studyAFP - Many parents give their children too large or frequent doses of non-prescription medicines for fever, coughs and colds, putting their health at risk, according to an Australian study released Monday... more >>Sun, 29 Aug 2010 Some Fake ADHD to Get Meds, Special TreatmentHD - While attention-deficit hyperactivity disorder (ADHD) is a real and pervasive condition, new research suggests there is a cluster of kids and adults who successfully fake the condition either to get drugs or gain special privileges in school... more >>Sat, 28 Aug 2010 Prescription Painkillers Could Be New 'Gateway' DrugsHD - Prescription medicines are the way that many drug addicts first get hooked, making these legal medicines the new "gateway" drugs, new study findings show... more >>Sat, 28 Aug 2010 FDA gets tougher with certain drug trialsReuters - The U.S. Food and Drug Administration is cracking down on use of certain clinical trials that show a new drug is no worse than another already on the market, according to a government report released on Friday... more >>Fri, 27 Aug 2010 Does Hope Have a Dark Side?HD - Imagine suffering from a chronic illness that challenges you every single day. You have aches and pains, difficulty getting around and sometimes suffer from surprising decreases in energy. You take fistfuls of medication for relief and endure countless medical procedures to keep the illness from progressing... more >>Fri, 27 Aug 2010 African police seize 10 metric tons of fake medsReuters - Police seized about 10 metric tons of counterfeit medicines and arrested 80 people in a sweep across eastern Africa, international police agency Interpol said on Thursday... more >>Thu, 26 Aug 2010 In Some Patients, Hypertension Meds Raise Blood PressureHD - Popular prescription medications taken to control hypertension may actually boost blood pressure in a "statistically significant" percentage of patients, researchers report... more >>Thu, 26 Aug 2010 Cognitive Therapy Helps Adults With ADHDHD - Adding therapy to the medications an adult might be taking for attention-deficit/hyperactivity disorder (ADHD) could lessen symptoms and improve quality of life, new research suggests... more >>Wed, 25 Aug 2010 | ||
|
vermox.org © 2007 Vermox
Vermox Consumer Information MedFacts, Cerner Multum, Micromedex, PDR and Professional Monographs (FDA) | ||||